Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

Rainer Porschen(Klinikum Bremen-Mitte), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Axel Grothey(Campbell Clinic), Werner Freier(Mayo Clinic in Florida), Thomas Seufferlein(Universität Ulm), Ullrich Graeven(Kliniken Maria Hilf), Axel Hinke, Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), S. Kubicka(Mayo Clinic in Florida), Albrecht Kretzschmar(Roche (Switzerland)), Richard Greil(Paracelsus Medical University)
Journal of Clinical Oncology
June 5, 2007
10.1200/jco.2006.09.2684
Cited by 281

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k